Atlas Trials

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Clinical trial NCT07134556 · WITHDRAWN

Trial details

NCT number
NCT07134556
Sponsor
MedSIR
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Triple Negative Breast CancerPDL-1 Positive
Start date
2026-04-01
Primary completion
2028-05-28
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.